<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03723135</url>
  </required_header>
  <id_info>
    <org_study_id>CC-486</org_study_id>
    <nct_id>NCT03723135</nct_id>
  </id_info>
  <brief_title>Expanded Access for CC-486</brief_title>
  <official_title>Expanded Access for CC-486</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <brief_summary>
    <textblock>
      This is an expanded access program (EAP) for eligible participants designed to provide access&#xD;
      to CC-486.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Acute Myelogenous Leukemia (AML)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-486</intervention_name>
    <description>Oral azacitidine administered as directed by treating physician.</description>
    <other_name>Oral Azacitidine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -Adult patients with documented acute myelogenous leukemia (AML) in their first complete&#xD;
        remission (CR) or complete remission with incomplete blood count recovery (CRi) following&#xD;
        induction therapy with or without consolidation treatment, who seek treatment with CC-486&#xD;
        as monotherapy to maintain their CR or CRi.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with AML in CR/CRi who plan to proceed to or are waiting for a bone marrow&#xD;
             transplant&#xD;
&#xD;
          -  Patients who have received a bone marrow transplant for the treatment of AML&#xD;
&#xD;
          -  Treatment of AML patients with relapse or refractory disease&#xD;
&#xD;
          -  Pregnant or breast-feeding females&#xD;
&#xD;
          -  Patient meets enrollment criteria and can participate in a disease-specific clinical&#xD;
             trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Celgene</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 25, 2018</study_first_submitted>
  <study_first_submitted_qc>October 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2018</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Expanded Access</keyword>
  <keyword>Compassionate Use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Cc-486</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

